Premium
Teniposide, dexamethasone and continuous‐infusion cyclophosphamide in advanced refractory myeloma
Author(s) -
Leoni Franco,
Ciolli Stefania,
Salti Franco,
Teodori Paolo,
Ferrini Pierluigi Rossi
Publication year - 1991
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1991.tb07974.x
Subject(s) - teniposide , medicine , melphalan , dexamethasone , cyclophosphamide , refractory (planetary science) , toxicity , chemotherapy , salvage therapy , surgery , oncology , etoposide , physics , astrobiology
Summary Twenty‐one patients with advanced refractory myeloma (nine primary unresponsive to melphalan, 12 relapsed and resistant to first‐line salvage therapy) received monthly 7 d courses of cyclophosphamide by continuous infusion, associated with teniposide and dexamethasone. Six patients died within 2 months from start of treatment, before receiving an adequate trial. Among the 15 evaluable patients, there were eight objective responses and three improvements (decrease of monoclonal protein > 50% or > 30%, respectively). After a median follow‐up of 10 months, all responding patients are alive and none of them is still relapsed. In heavily pretreated patients, ineligible for more aggressive approaches, cyclophosphamide by continuous‐infusion exerted a good antineoplastic activity without increasing toxicity.